LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Canertinib | 10 | uM | LJP6 | 72 | hr | 1657 | 1183 | 5383 | 0.2198 | -0.1810 |
BT-20 | NVP-AEW541 | 0.04 | uM | LJP5 | 72 | hr | 1657 | 5806 | 5588 | 1.0395 | 1.0444 |
BT-20 | NVP-AEW541 | 0.12 | uM | LJP5 | 72 | hr | 1657 | 5821 | 5588 | 1.0417 | 1.0470 |
BT-20 | NVP-AEW541 | 0.37 | uM | LJP5 | 72 | hr | 1657 | 5765 | 5588 | 1.0319 | 1.0357 |
BT-20 | NVP-AEW541 | 1.11 | uM | LJP5 | 72 | hr | 1657 | 5604 | 5588 | 1.0032 | 1.0034 |
BT-20 | NVP-AEW541 | 3.33 | uM | LJP5 | 72 | hr | 1657 | 5837 | 5588 | 1.0449 | 1.0507 |
BT-20 | NVP-AEW541 | 10 | uM | LJP5 | 72 | hr | 1657 | 5335 | 5588 | 0.9547 | 0.9472 |
BT-20 | PHA-665752 | 0.04 | uM | LJP5 | 72 | hr | 1657 | 5634 | 5588 | 1.0085 | 1.0095 |
BT-20 | PHA-665752 | 0.12 | uM | LJP5 | 72 | hr | 1657 | 5904 | 5588 | 1.0568 | 1.0639 |
BT-20 | PHA-665752 | 0.37 | uM | LJP5 | 72 | hr | 1657 | 5605 | 5588 | 1.0030 | 1.0029 |
BT-20 | PHA-665752 | 1.11 | uM | LJP5 | 72 | hr | 1657 | 5697 | 5588 | 1.0198 | 1.0224 |
BT-20 | PHA-665752 | 3.33 | uM | LJP5 | 72 | hr | 1657 | 5638 | 5588 | 1.0088 | 1.0098 |
BT-20 | PHA-665752 | 10 | uM | LJP5 | 72 | hr | 1657 | 4059 | 5588 | 0.7264 | 0.6666 |
BT-20 | PI103 | 0.04 | uM | LJP6 | 72 | hr | 1657 | 5425 | 5383 | 1.0075 | 1.0087 |
BT-20 | PI103 | 0.12 | uM | LJP6 | 72 | hr | 1657 | 4398 | 5383 | 0.8180 | 0.7771 |
BT-20 | PI103 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 2581 | 5383 | 0.4799 | 0.2982 |
BT-20 | PI103 | 1.11 | uM | LJP6 | 72 | hr | 1657 | 1749 | 5383 | 0.3248 | 0.0315 |
BT-20 | PI103 | 3.33 | uM | LJP6 | 72 | hr | 1657 | 1552 | 5383 | 0.2885 | -0.0380 |
BT-20 | PI103 | 10 | uM | LJP6 | 72 | hr | 1657 | 1434 | 5383 | 0.2665 | -0.0818 |
BT-20 | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 1657 | 4715 | 5588 | 0.8437 | 0.8140 |
BT-20 | Dovitinib | 0.12 | uM | LJP5 | 72 | hr | 1657 | 4026 | 5588 | 0.7202 | 0.6570 |
BT-20 | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 1657 | 3165 | 5588 | 0.5661 | 0.4396 |
BT-20 | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 1657 | 2850 | 5588 | 0.5098 | 0.3598 |
BT-20 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 1657 | 2475 | 5588 | 0.4428 | 0.2558 |
BT-20 | Dovitinib | 10 | uM | LJP5 | 72 | hr | 1657 | 2575 | 5588 | 0.4609 | 0.2855 |